Latest Natalizumab Stories
Natalizumab Was Well-Tolerated Under Double the Standard Dose Schedule NEW YORK, April 20, 2015 /PRNewswire-USNewswire/ -- Extending the dose of an infusion medication for multiple
MSology writer Steven Manners releases an up-to-date guide that enables people to make more informed decisions about their care. Montreal, Quebec (PRWEB) April
However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
TOORAK, Australia, Sept.
~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- Emitting flashes of light; glittering.